| 摘要: |
| ［摘要］ 目的 分析血清冠层成纤维细胞生长因子信号调节因子2（CNPY2）在胃癌中的表达水平及临床应用价值。方法 收集2023年12月至2024年9月山东第一医科大学附属省立医院胃肠外科收治的65例胃癌患者的临床资料。其中早期胃癌39例（TNM Ⅰ期），进展期胃癌26例（TNM Ⅱ期6例，TNM Ⅲ期17例，TNM Ⅳ期3例）。另选取该院同期胃部良性疾病患者43例作为良性组，以及体检健康者52名作为对照组。检测血清CNPY2、癌胚抗原（CEA）、糖类抗原199（CA199）水平。通过受试者工作特征(ROC)曲线分析CNPY2、CEA、CA199对胃癌和早期胃癌的诊断效能。结果 胃癌组CNPY2的中位浓度0.26 ng/mL高于良性组的0.21 ng/mL和对照组的0.21 ng/mL，胃癌组CEA的中位浓度2.21 ng/mL高于良性组的1.28 ng/mL和对照组的1.32 ng/mL，胃癌组CA199的中位浓度13.70 IU/mL高于对照组的9.26 IU/mL，差异有统计学意义（P<0.05）。TNM Ⅱ～Ⅳ期胃癌患者（22例）CNPY2的中位浓度0.27 ng/mL、CA199的中位浓度16.95 IU/mL分别高于TNM Ⅰ期胃癌患者（36例）CNPY2的中位浓度0.24 ng/mL、CA199的中位浓度11.05 IU/mL，低分化胃癌患者（34例）CNPY2的中位浓度0.27 ng/mL高于中高分化胃癌患者（24例）的0.25 ng/mL，人表皮生长因子受体2（HER2）阴性胃癌患者（18例）CEA的中位浓度3.44 ng/mL高于HER2阳性胃癌患者（40例）的1.88 ng/mL，差异有统计学意义（P<0.05）。ROC曲线分析结果显示，CNPY2、CEA、CA199联合诊断胃癌［AUC（95%CI）=0.885(0.823～0.947)］和早期胃癌［AUC（95%CI）=0.857(0.780～0.933)］的效能较单项指标更高（P<0.05）。结论 胃癌患者血清CNPY2水平明显升高，血清CNPY2、CEA、CA199联合检测可提高对胃癌和早期胃癌的诊断效能。 |
| 关键词: 胃癌 早期胃癌 冠层成纤维细胞生长因子信号调节因子2 癌胚抗原 糖类抗原199 |
| DOI：10.3969/j.issn.1674-3806.2025.02.07 |
| 分类号: |
| 基金项目:山东省自然科学基金项目（编号：ZR2023QH463） |
|
| The expression level and clinical application value of serum CNPY2 in gastric cancer |
|
CHEN Lanlan1,2, JU Ying2, LIU Duanrui2, LIU Yiqing2, LIU Yun2, ZHANG Peili1,2, PENG Meiyu1
|
|
1.Department of Basic Immunology, Shandong Second Medical University, Weifang 261053, China; 2.Department of Clinical Medical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Ji′nan 250021, China
|
| Abstract: |
| ［Abstract］ Objective To analyze the expression level and clinical application value of serum canopy fibroblast growth factor signaling regulator 2(CNPY2) in gastric cancer. Methods The clinical data of 65 gastric cancer patients hospitalized in the Department of Gastrointestinal Surgery of Shandong Provincial Hospital Affiliated to Shandong First Medical University from December 2023 to September 2024 were collected. Among the patients, there were 39 cases of early gastric cancer(TNM stage Ⅰ) and 26 cases of progressive gastric cancer(6 cases of TNM stage Ⅱ, 17 cases of TNM stage Ⅲ and 3 cases of TNM stage Ⅳ). Other 43 cases of patients with benign gastric diseases in Shandong Provincial Hospital Affiliated to Shandong First Medical University were selected as the benign group during the same period, and 52 cases of healthy individuals undergoing physical examination were selected as the control group. The levels of serum CNPY2, carcinoembryonic antigen(CEA) and carbohydrate antigen 199(CA199) were detected. The diagnostic efficacy of CNPY2, CEA, and CA199 for gastric cancer and early gastric cancer was analyzed by using receiver operating characteristic(ROC) curve. Results The median concentration of CNPY2 in the gastric cancer group(0.26 ng/mL) was higher than that in the benign group(0.21 ng/mL) and the control group(0.21 ng/mL), and the median concentration of CEA in the gastric cancer group(2.21 ng/mL) was higher than that in the benign group(1.28 ng/mL) and the control group(1.32 ng/mL), and the median concentration of CA199 in the gastric cancer group(13.70 IU/mL) was higher than that in the control group(9.26 IU/mL), and the differences were statistically significant(P<0.05). The median concentrations of CNPY2(0.27 ng/mL) and CA199(16.95 IU/mL) in gastric cancer patients with TNM stage Ⅱ to stage Ⅳ(22 cases) were higher than the median concentrations of CNPY2(0.24 ng/mL) and CA199(11.05 IU/mL) in gastric cancer patients with TNM stage Ⅰ(36 cases), and the patients with poorly differentiated gastric cancer(34 cases) had a higher median concentration of CNPY2(0.27 ng/mL) than the patients with moderately to highly differentiated gastric cancer(24 cases)(0.25 ng/mL), and the median concentration of CEA(3.44 ng/mL) in the gastric cancer patients with human epidermal growth factor receptor 2(HER2) negative(18 cases) was higher than the median concentration of CEA(1.88 ng/mL) in the gastric cancer patients with HER2 positive(40 cases), and the differences were statistically significant(P<0.05). The results of ROC curve analysis showed that using the combination of CNPY2, CEA and CA199 in diagnosis of gastric cancer［AUC(95%CI)=0.885(0.823-0.947)］ and early gastric cancer［AUC(95%CI)=0.857(0.780-0.933)］ had higher efficacy than using CNPY2, CEA and CA199 alone(P<0.05). Conclusion Serum CNPY2 levels are significantly elevated in patients with gastric cancer, and the combined detection of serum CNPY2, CEA and CA199 can improve the diagnostic efficacy of gastric cancer and early gastric cancer. |
| Key words: Gastric cancer Early gastric cancer Canopy fibroblast growth factor signaling regulator 2(CNPY2) Carcinoembryonic antigen(CEA) Carbohydrate antigen 199(CA199) |
